View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 14, 2021updated 16 Apr 2021 5:21am

Moderna’s Covid-19 variant vaccines boost neutralising titers in study

Moderna's Covid-19 variant vaccines showed an increase in neutralising titers against SARS-CoV-2 variants of concern according to the latest data from a preclinical study of its candidates mRNA-1273.351 and mRNA-1273.211.

Moderna’s Covid-19 variant vaccines showed an increase in neutralising titers against SARS-CoV-2 variants of concern according to the latest data from a preclinical study of its candidates mRNA-1273.351 and mRNA-1273.211.

mRNA-1273.351 is a vaccine more specifically targeted against the SARS-CoV-2 variant known as B.1.351 and first detected in South Africa.

A multivalent booster candidate, mRNA-1273.211 combines Moderna’s authorised vaccine against ancestral strains (mRNA-1273) and mRNA-1273.351 in a single vaccine.

Data from the study on Balb/c mice confirmed enhanced neutralising titers with the mRNA-1273.351 vaccine primary series. A boost with mRNA-1273.351 at six months closed the neutralising titer gap for the variants.

On administering mRNA-1273.351, neutralising titers were similar between the ancestral strain (Wuhan) and the new B.1.351 variant.

Moderna CEO Stéphane Bancel said: “We are looking forward to having the clinical data from our variant-specific booster candidates, as well as clinical data from the phase II/III study of our Covid-19 vaccine in adolescents.

“The new preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants. Moderna will make as many updates to our Covid-19 vaccine as necessary until the pandemic is under control.”

The company also provided an update from the phase III COVE study of the Moderna Covid-19 vaccine, which showed a continued strong efficacy with over 90% against Covid-19 cases and over 95% against severe disease at six months median follow-up after the second dose.

Moderna has so far supplied approximately 132 million doses of the vaccine globally.

On another note, Medolife has filed its final set of data sought by the US Food and Drug Administration (FDA) for its Pre-Investigational New Drug (IND) filing on its lead drug candidate Escozine for Covid-19 treatment.

Escozine is Medolife’s polarised solution of the Rhopalurus princeps scorpion peptide.

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy